Probiotics, irritable bowel syndrome, and inflammatory bowel disease

被引:26
作者
Martin H. Floch
机构
[1] Yale University School of Medicine,Department of Medicine
关键词
Inflammatory Bowel Disease; Lactobacillus; Ulcerative Colitis; Irritable Bowel Syndrome; Lactobacillus Plantarum;
D O I
10.1007/s11938-003-0020-y
中图分类号
学科分类号
摘要
Probiotics are live, microbial food supplements that benefit the host animal by improving intestinal microbial balance. Their major role in preventing and treating gastrointestinal disease appears to be from their effect on the immune process, protection against abnormal invasive bacteria, and in the production of short-chain fatty acids from starch and non-starch polysaccharides. Probiotic microorganisms are administered in food supplements and yogurts. They are also now sold in the form of capsules and powders. There is great variation in the microorganisms in the various supplements. It is important to understand that all probiotic products are different. Some contain a single organism and others contain multiple organisms. Therapeutic results have been achieved with various probiotics in different diseases. In the treatment of inflammatory bowel diseases (IBD), success has been reported with Escherichia coli Nissle strain in ulcerative colitis, and with a multiple organism product, VSL#3 (VSL Pharmaceuticals, Fort Lauderdale, FL), in Crohn’s disease and pouchitis. Initial reports in irritable bowel syndrome (IBS) have resulted in encouraging results with the use of E. coli Nissle strain, and recently with multiple organism probiotic supplements. However, caution must still apply to the use of probiotics in IBD and IBS because the reports and the number of patients treated are limited.
引用
收藏
页码:283 / 288
页数:5
相关论文
共 94 条
[21]  
D’Haens G(2003)Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon Gut 52 237-242
[22]  
Targan S(2002)Mucosal flora in inflammatory bowel disease Gastroenterology 122 44-54
[23]  
Borruel N(2003)Use of probiotics in the treatment of inflammatory bowel disease J Clin Gastroenterol 36 111-119
[24]  
Carol M(1993)Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea—a pilot study Z Gastroenterol 31 129-134
[25]  
Casellas F(2000)Saccharomyces boulardii in maintenance treatment of Crohn’s disease Dig Dis Sci 45 1462-1464
[26]  
Li Z(2002)Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomized controlled trial with Lactobacillus GG Gut 51 405-409
[27]  
Yang S(2000)Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrent of Crohn’s disease: a randomised controlled study versus mesalazine Gastroenterology 118 A781-A781
[28]  
Lin H(2002)Once daily high dose probiotic therapy maintains remission and improves quality of life in patients with recurrent or refractory pouchitis: a randomised, placebo-controlled, double-blind trial Gastroenterology 122 A81-A81
[29]  
Sheih YH(2001)Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment Am J Gastroenterol 96 2691-2699
[30]  
Chiang BL(2002)Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome Dig Dis Sci 47 2615-2620